Basic Information
Symbol
circUBAP2
RNA Class
circRNA
Alias
Ubiquitin Associated Protein 2
KIAA1491
RNA Polymerase II Degradation Factor UBAP2
Ubiquitin-Associated Protein 2
BA176F3.5
FLJ22435
UBAP-2
AD-012 Protein
Location (GRCh37)
9:33817819-34048885
UCSC Genome Browser
Location (GRCh38)
9:33817821-34048887
Host gene
UBAP2
Host category
mRNA
Forensic tag(s)
Sudden cardiac death diagnosis
External database
Transcripts
| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_UBAP2_0009500 | Exon-Exon | chr9:33948372-33971752 | chr9:33948374-33971754 | 695 nt | 0.4849 |
| hsa_UBAP2_0009700 | Exon-Exon | chr9:33948372-33989124 | chr9:33948374-33989126 | 436 nt | 0.4679 |
| hsa_UBAP2_0009800 | Exon-Exon | chr9:33948372-34017187 | chr9:33948374-34017189 | 218 nt | 0.3899 |
| hsa_UBAP2_0009900 | Exon-Exon | chr9:33948395-33953472 | chr9:33948397-33953474 | 197 nt | 0.4975 |
| hsa_UBAP2_0010000 | Exon-Exon | chr9:33948444-33956129 | chr9:33948446-33956131 | 53 nt | 0.5094 |
| hsa_UBAP2_0011100 | Intron-Exon-Intron | chr9:33953283-33974204 | chr9:33953285-33974206 | 1505 nt | 0.4173 |
| hsa_UBAP2_0011300 | Intron-Exon-Intron | chr9:33953283-34014623 | chr9:33953285-34014625 | 258 nt | 0.5155 |
| hsa_UBAP2_0011400 | Intron-Exon-Intron | chr9:33953283-34037692 | chr9:33953285-34037694 | 38 nt | 0.5526 |
| hsa_UBAP2_0011600 | Intron-Intron | chr9:33953875-33954018 | chr9:33953877-33954020 | 144 nt | 0.4653 |
| hsa_UBAP2_0011800 | Intron-Exon-Intron | chr9:33956077-33957083 | chr9:33956079-33957085 | 1007 nt | 0.4598 |
Showing 151 to 160 of 263 entries
Forensic Context
A review of literature indicates that the circUBAP2 is an oncogenic circular RNA upregulated in osteosarcoma patient samples, where its high expression is correlated with lower overall survival and promotes tumor growth while inhibiting apoptosis [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A study in human patients with heart failure after acute myocardial infarction demonstrated that the expression level of the circUBAP2 was not significantly different between patients with sacubitril/valsartan resistance and non-resistant patients in quantitative real-time PCR validation [Su et al. DOI:10.1016/j.ejphar.2023.175547].